Presentation is loading. Please wait.

Presentation is loading. Please wait.

Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV.

Published byAugustus Claytor Modified over 9 years ago

Similar presentations

Presentation on theme: "Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV."— Presentation transcript:

1 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV – Is your patient being left behind? New options and unmet needs., Kuala Lumpur, Malaysia Jürgen K. Rockstroh Department of Internal Medicine I University Hospital Bonn Germany

2 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Disclosure slide: Jürgen Rockstroh Receipt of grants/research supports: – Gilead Receipt of honoraria or consultation fees: – Abbvie, Abbott, Bionor. BMS, Boehringer, Gilead, GSK, Janssen, Merck, Novartis, Tobira, ViiV

3 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage: Virologic non-responders and relapsers

4 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 EACS guidelines 2012

5 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Cotte L, et al. 20th CROI; Atlanta, GA; March 3-6, 2013. Abst. 36. Telaprevir + PegIFN + RBV in HIV/HCV Co-infected Patients with Virologic Failure on IFN + RBV Complete RVR 8 (HCV-RNA <15 IU/mL): 32 weeks PR phase (Total treatment: 48 weeks) Partial RVR 8 (15 IU/mL <HCV-RNA <1,000 IU/mL) 56 weeks PR phase (Total treatment: 72 weeks) Single Arm, Phase 2 Clinical Trial (Lead in) PegIFN α-2a RBV Telaprevir PegIFN α-2a RBV PegIFN α-2a RBV Follow-upFollow-up Follow-upFollow-up D0W4W8 RVR 8 W16 EVR 16 W48W72 SVR 24 W96 SVR 24 Complete RVR 8 Partial RVR 8

6 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Cotte L, et al. 20th CROI; Atlanta, GA; March 3-6, 2013. Abst. 36. Telaprevir + PegIFN + RBV in HIV/HCV Co-infected Patients with Virologic Failure on IFN + RBV Main Inclusion Criteria – Chronic HCV genotype 1 infection and HIV-1 infection – Previous virological failure after ≥12 weeks PegIFN + RBV ≥600 mg/day – Stable ART for ≥3 months – Authorized antiretrovirals: ATV, ATVr, EFV, RAL, TDF, FTC, 3TC – CD4 ≥200 cells/mm 3 and ≥15%, plasma HIV-RNA levels <50 copies/mL – Liver biopsy <3 years or cirrhosis on any previous biopsy Main Exclusion Criteria – HVB coinfection, HIV-2 infection – Past history of decompensated cirrhosis – Previous null response with cirrhosis Important patient characteristics – F3 16%, F4 23%; HCV GT1a 70%

7 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Virological response (ITT, n=69) Only 3 patients with partial RVR 8  treatment 72 weeks RVR 8 EVR 16 7 TND 88%

8 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Telaprevir + Peg-IFN + RBV in HIV/HCV co- infected patients with virologic failure on IFN + RBV: Early virologic response by patient group Cotte L, et al. 20th CROI; Atlanta, GA; March 3-6, 2013. Abstract 36 n=34131210123011162761521 ATVr EFV RAL Others F1F2F3F4RR BrkTh PRNR

9 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Grade 3 – 4 AEs and treatment discontinuations up to W16 N (%), n=69 Grade 3 AEs Blood General GI Cutaneous Neurological Psychiatric Others 18 (26%) 6 (9%) 5 (7%) 2 (3%) 3 (4%) 2 (3%) 1 (1%) 2 (3%) Grade 4 AEs Blood Psychiatric 5 (7%) 4 (6%) 1 (1%) Reasons for treatment discontinuations Psychiatric AEs Cutaneous AEs Others AEs Virological failure 3 (4%) 1 (1%)

10 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Boceprevir + PegIFN + RBV for HIV-HCV Co-Infected Patients with Previous Virologic Failure on PegIFN + RBV **BOC+ PegIFN + RBV **BOC+ PegIFN + RBV W8 15≤HCV VL- ≤1,000 IU/mL BOC+ PegIFN + RBV W8 15≤HCV VL- ≤1,000 IU/mL BOC+ PegIFN + RBV Weeks * *PegIFN + RBV W12-HCV VL> 1,000 IU/ mL: PegIFN + RBV PegIFN + RBV W12- 15< HCV VL≤ 1,000 IU/ mL BOC+ PegIFN + RBV W12- 15< HCV VL≤ 1,000 IU/ mL BOC+ PegIFN + RBV Follow-up Follow-up 281216048724896 Lead- in Phase * PegIFNα2b: 1.5 μg/kg/wk RBV: 800 to 1,400 mg/day ** BOC:800 mg 3 times/ day Stop BOC Stop All Drugs RVR8: % HCV RNA <15 IU/mL EVR16:% HCV RNA <15 IU/mL EPO, G-CSF, TPO-R agonists allowed Pizot-Martin I, et al. 20th CROI; Atlanta, GA; March 3-6, 2013. Abst. 37. Study Design HCV VL > 1,000 IU/mL SVR 24 W72 Follow-up W8-HCV VL < 15 IU/ mL: BOC+ PegIFN + RBV SVR 24 W96 W8-HCV VL > 1,000 IU/ mL: PegIFN + RBV Follow-up HCV RNA > 100 IU/mL

11 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Inclusion/Exclusion Criteria Inclusion – body weight 40-125 kg – Chronic HCV genotype 1 – Previous virologic failure on PegIFN + RBV – Stable antiretroviral therapy with 3 or more ARV agents among TDF, ABC, FTC, 3TC, ATV (boosted or not), and RAL – CD4+ count ≥200 cells/mm 3 and VL <50 c/mL for ≥6 months – Any fibrosis level on liver bx within past 3 years or any bx showing cirrhosis Exclusion – HBV co-infection – Childs B or C; decompensated cirrhosis – Previous null response with cirrhosis Important patient characteristics – F4 17%; previous null responders 33%, GT1a 78% Pizot-Martin I, et al. 20th CROI; Atlanta, GA; March 3-6, 2013. Abst. 37.

12 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 BOC/IFN/RBV following virologic failure: results by previous response to Peg-IFN + RBV Pizot-Martin I, et al. 20th CROI; Atlanta, GA; March 3–6, 2013. Abstract 37 RVR 8 EVR 16

13 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 BOC/IFN/RBV following virologic failure: Results by ARV regimen Pizot-Martin I, et al. 20th CROI; Atlanta, GA, 2013; Abstract 37 RVR 8 EVR 16

14 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 F0F1 F2F3 F4 NaiveRelapser Nonresponder Individual decision Individual decision/ triple therapy Defer Triple therapy Individual decision according to disease progression Triple therapy Management of HIV-HCV GT1-co-infected patients (chronic) according to prior treatment outcome Ingiliz P. & Rockstroh J. Liver Int 2012;32:1194–9; EACS guidelines version November 2012

15 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 EACS guidelines 2012

16 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage: Non-genotype 1

17 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Pivotal RCTs for Peg-IFN/RBV in HIV/HCV co-infection 1. Carrat F, et al. JAMA 2004;292:2839–48; 2. Laguno M, et al. Hepatology 2009;49:22–31; 3. Chung RT, et al. N Engl J Med 2004;351:451–9; 4. Torriani FJ, et al. N Engl J Med 2004;351:438–50; 5. Núñez M, et al. AIDS Res Hum Retroviruses 2007;23:972–82 StudyRegimen SVR (%) G1 or G4 SVR (%) G2 or G3 Take home observations RIBAVIC 1 France (N = 412) Peg-IFN α-2b RBV 800 mg 1744 Low-dose RBV Toxicity with ddI + RBV Failure to suppress HCV RNA at week 4 <460,000 IU/mL → 100% NPV Laguno et al 2 Spain (N =182) Peg-IFN α-2b RBV 800 – 1200 mg 2862 Weight-based RBV → higher SVR Short (24-week) therapy for genotype 2/3 not effective ACTG A5071 3 USA (N = 133) Peg-IFN α-2a RBV 600 - 1000 mg 1473 Low-dose RBV Failure to achieve week 12 EVR → 100% NPV ZDV + RBV → more anemia APRICOT 4 International (N = 868) Peg-IFN α-2a RBV 800 mg 2962 Low-dose RBV Decompensation with advanced fibrosis Genotype 1/High HCV RNA –18% SVR PRESCO 5 Spain (N = 389) Peg-IFN α-2a RBV 1000 – 1200 mg 3572 Weight-based RBV → higher SVR No increase in anemia Long (72-week) therapy not well tolerated

18 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 EACS guidelines 2012

19 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Ongoing clinical trials in HIV/HCV coinfection PHOTON 1 and 2 Studies: GT1 or 4 HIV/HCV co-infected treatment- naïve (TN) and GT- 2/3 TN and Experienced Subjects with sofosbuvir + RBV 12-24 weeks

20 www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013

Download ppt "Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 How to manage virologic non- responders, non-genotype 1, relapsers IAS 2013, Session: HCV."

Similar presentations

HIV/HCV Coinfection News – HCV Protease Inhibitors

HIV/HCV Coinfection News – HCV Protease Inhibitors
Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Access to HCV triple therapy with Telaprevir or Boceprevir in a real-life setting in HIV-HCV.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Access to HCV triple therapy with Telaprevir or Boceprevir in a real-life setting in HIV-HCV.
STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV Douglas.

STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV Douglas.
Www.ias2013.org Kuala Lumpur, Malaysia, 30 June - 3 July 2013 At the Heart of Longevity Cardiovascular Health A good head and a good heart are always a.

Kuala Lumpur, Malaysia, 30 June - 3 July 2013 At the Heart of Longevity Cardiovascular Health A good head and a good heart are always a.
Www.aids2014.org Use of efavirenz is not associated to an increased risk of neurocognitive impairment in HIV-infected patients Pinnetti C 1, Balestra P.

Use of efavirenz is not associated to an increased risk of neurocognitive impairment in HIV-infected patients Pinnetti C 1, Balestra P.
Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.

Current Status and Benefits of Therapy for Chronic Hepatitis C Virus (HCV) Fuad AM Hasan Department Of Medicine Faculty of Medicine Kuwait University.
Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.

Future Trials of Hepatitis C Therapy in the HIV Co-infected Stephen D. Shafran, MD, FRCPC, FACP Department of Medicine, Division of Infectious Diseases.
Www.aids2014.org HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.

HCV cure: new treatment paradigms for HCV infection Sanjay Bhagani Consultant Physician/Senior Lecturer Royal Free Hospital/UCL London.
Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.

Future Directions in HCV Therapy Eric Lawitz, MD, AGAF,CPI Medical Director, The Texas Liver Institute Clinical Professor of Medicine University of Texas.
Hepatitis C & HIV in 2011 Vincent Soriano Infectious Diseases Department Hospital Carlos III, Madrid, Spain.

Hepatitis C & HIV in 2011 Vincent Soriano Infectious Diseases Department Hospital Carlos III, Madrid, Spain.
Washington D.C., USA, 22-27 July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.

Washington D.C., USA, July 2012www.aids2012.org Access to HCV treatment for people with HIV/HCV Professor Gregory Dore Viral Hepatitis Clinical Research.
Advances in the Treatment of Chronic Hepatitis C Gregory T Everson, MD Professor of Medicine Director of Hepatology University of Colorado Denver.

Advances in the Treatment of Chronic Hepatitis C Gregory T Everson, MD Professor of Medicine Director of Hepatology University of Colorado Denver.
Hcv infection and management in advanced liver disease

Hcv infection and management in advanced liver disease
Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.

Slide 1 of 8 From DL Wyles, MD, at Atlanta, GA: April 10, 2013, IAS-USA. IAS–USA David L. Wyles, MD Associate Professor of Medicine University of California.
Protease and Polymerase Inhibitors for the Treatment of Hepatitis C

Protease and Polymerase Inhibitors for the Treatment of Hepatitis C
Interferon-free 3 DAA Plus Ribavirin Regimen in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine 20 th International AIDS Conference Melbourne,

Interferon-free 3 DAA Plus Ribavirin Regimen in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine 20 th International AIDS Conference Melbourne,
Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.

Hepatitis web study Hepatitis web study Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON Phase 3 *Note: Published in tandem with FUSION Trial.
Direct Acting Antivirals: What are they

Direct Acting Antivirals: What are they
TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 20 th International.

TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 20 th International.
Welcome and Introduction Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Ian Frank, MD Moderator: John Bartlett, MD Discussants: Cal Cohen, MD.

Welcome and Introduction Moderator: John Bartlett, MD Discussants: Cal Cohen, MD Ian Frank, MD Moderator: John Bartlett, MD Discussants: Cal Cohen, MD.

Similar presentations

Ads by Google